OK, Boomer
New Users, Different Platforms, New Challenges
The popularization of new interaction spaces brings new narratives and social phenomena that merit attention from the scientific community. Based on the existing literature on the new challenges facing the communication discipline with these emerging narratives, this editorial summarizes the empirical and theoretical contributions of the thematic issue entitled “New Narratives for New Consumers: Influencers and the Millennial and Centennial Generations.” The authors emphasize that the studies selected for this thematic issue explore the innovative features and opportunities of the emerging scenarios and offer a cautionary account of their structural problems and the urgency of a new media literacy.
Romero-Rodríguez, L.M., Tejedor, S., & Berlanga, I. (2022). OK, Boomer: New Users, Different Platforms, New Challenges. Media and Communication, 10(1). https://doi.org/10.17645/mac.v10i1.5050
Other Publications
Apomediation and Disintermediation: YouTube Prescribers on Fad Diets
Patterns and Actors of Disinformation: Analysis of Debunked Hoaxes in Spain in 2022
Audiovisual content viewing practices and the psychosocial sentiment of political efficacy in younger audiences from Spain and Mexico
Audiovisual in the streaming era: Millennials’ and centennials’ perspectives on cruelty and historical truthfulness
Impact of Teaching Workload on Scientific Productivity: Multidimensional Analysis in the Complexity of a Mexican Private University
Owned media, influencer marketing, and unofficial brand ambassadors: differences between narratives, types of prescribers, and effects on interactions on Instagram
Journalism on Forced Migration in Latin America: Recommendations from Experts and International Journalism Guides from a Qualitative Study
‘Millennials and centennials’ perspective on Streaming narratives in Spain and Mexico: Spiral of silence, bandwagon effect, and third person effect
Iconographic-symbolic analysis model of Corporate Visual Identity (CVI): Application test on pharmaceutical companiesin Spain